The P value in a small trial is generally reflective of the small sample size rather than efficacy. If you combine all the data such as survival, NFL changes and AFS score, you see they all suggest that MPL is slowing disease progression. Add to that the significant improvement gained from the increased dosage enjoyed by cohort 2 and it's hard to prescribe any other reason for the improvements other than that MPL is effective in treating MND/ALS. With consistent data correlation I'd put p value at .001. I may be wrong, it's probably better than that.
The P value in a small trial is generally reflective of the...
-
- There are more pages in this discussion • 471 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $92.38M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $70.59K | 380.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 220000 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 89682 | 4 |
View Market Depth
| Last trade - 10.42am 05/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |